ZIOPHARM Oncology (ZIOP) Shares Down 6.5%
Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) dropped 6.5% during trading on Wednesday . The stock traded as low as $4.11 and last traded at $4.15. Approximately 1,462,722 shares traded hands during trading, a decline of 14% from the average daily volume of 1,706,118 shares. The stock had previously closed at $4.44.
Several brokerages recently weighed in on ZIOP. Zacks Investment Research lowered shares of ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a research report on Thursday, December 20th. BidaskClub lowered shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, December 22nd. Laidlaw began coverage on shares of ZIOPHARM Oncology in a research report on Monday, April 1st. They set a “buy” rating and a $7.50 price objective on the stock. Finally, Lake Street Capital began coverage on shares of ZIOPHARM Oncology in a research report on Thursday, April 4th. They set a “buy” rating and a $7.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $5.85.
The stock has a market cap of $709.19 million, a price-to-earnings ratio of -8.65 and a beta of 2.63.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Legal & General Group Plc raised its position in ZIOPHARM Oncology by 30.6% during the fourth quarter. Legal & General Group Plc now owns 25,865 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 6,054 shares in the last quarter. Northern Trust Corp raised its position in shares of ZIOPHARM Oncology by 0.5% in the fourth quarter. Northern Trust Corp now owns 1,647,754 shares of the biotechnology company’s stock valued at $3,081,000 after purchasing an additional 8,068 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of ZIOPHARM Oncology by 57.2% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 47,069 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 17,130 shares during the period. Amalgamated Bank bought a new position in shares of ZIOPHARM Oncology in the fourth quarter valued at approximately $37,000. Finally, Allred Capital Management LLC bought a new position in shares of ZIOPHARM Oncology in the fourth quarter valued at approximately $40,000. 38.01% of the stock is currently owned by hedge funds and other institutional investors.
About ZIOPHARM Oncology (NASDAQ:ZIOP)
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
Featured Article: Key terms to understand channel trading
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.